Completed PHASE1 INTERVENTIONAL NCT00080054

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas

Sponsor: Pharmacyclics LLC.

Conditions Astrocytoma Brain Neoplasm Glioblastoma Glioma Oligodendroglioma

Interventions Motexafin Gadolinium Injection

Updated 5 times since 2017 Last updated: Apr 2, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00080054, this PHASE1 trial focuses on Astrocytoma and Brain Neoplasm and remains completed. Sponsored by Pharmacyclics LLC., it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmacyclics LLC.

Data source: Pharmacyclics LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States